Nkengasong J N, Kalou M, Maurice C, Bile C, Borget M Y, Koblavi S, Boateng E, Sassan-Morokro M, Anatole-Ehounou E, Ghys P, Greenberg A E, Wiktor S Z
Projet RETRO-CI, CHU Treichville, Abidjan, Côte d'Ivoire.
J Clin Microbiol. 1998 Sep;36(9):2495-8. doi: 10.1128/JCM.36.9.2495-2498.1998.
We compared the sensitivity and accuracy of the NucliSens assay and those of both the standard and modified (addition of a new primer set, primer mix 1, supplied by Roche) Amplicor HIV Monitor assays to quantify human immunodeficiency virus type 1 (HIV-1) RNA in persons infected with HIV-1 subtype A in Abidjan, Côte d'Ivoire. Seventy-one plasma samples from HIV-1-seropositive persons at different stages of HIV infection and 15 samples from HIV antibody-negative persons were analyzed. The HIV-1 genetic subtype was determined either by DNA sequencing or by a restriction fragment length polymorphism assay. Of the 71 samples, 70 (98%) were subtype A and 1 was subtype G. Of the 70 subtype A samples, the proportion of RNA-positive plasma samples and mean HIV-1 RNA levels were significantly higher by the modified HIV Monitor assay (n = 67 [96%]; mean RNA levels, 5.2 log10 HIV-1 RNA copies/ml) than the NucliSens assay (n = 56 [80%]; 4.3 log10 HIV-1 RNA copies/ml) or the standard HIV Monitor assay (n = 44 [63%]; mean RNA levels, 3.8 log10 HIV-1 RNA copies/ml) (all P values were <0.05). The HIV-1 RNA levels by the modified HIV Monitor assay correlated significantly with those by the NucliSens assay (r = 0.76; P < 0.001) and the standard HIV Monitor assay (r = 0.57; P < 0.001), as did the RNA levels by the NucliSens and the standard HIV Monitor assays (r = 0.60; P < 0. 001). Lower CD4 cell counts were significantly correlated with higher HIV-1 RNA levels by all three assays (r = -0.47 for the NucliSens assay, -0.45 for the standard HIV Monitor assay, and -0.62 for the modified HIV Monitor assay). These results indicate that the modified HIV Monitor assay has the highest sensitivity and efficiency at quantifying the levels of RNA in persons infected with HIV-1 subtype A and thus constitutes a valuable tool for the monitoring of RNA levels in areas of Africa were HIV-1 subtype A is predominant.
我们比较了NucliSens检测法与标准及改良（添加罗氏公司提供的新引物组引物混合物1）的Amplicor HIV监测检测法在科特迪瓦阿比让对感染HIV-1 A亚型的人进行人类免疫缺陷病毒1型（HIV-1）RNA定量检测时的灵敏度和准确性。分析了来自处于HIV感染不同阶段的HIV-1血清阳性者的71份血浆样本以及来自HIV抗体阴性者的15份样本。通过DNA测序或限制性片段长度多态性检测法确定HIV-1基因亚型。在71份样本中，70份（98%）为A亚型，1份为G亚型。在70份A亚型样本中，改良后的HIV监测检测法（n = 67 [96%]；平均RNA水平为5.2 log10 HIV-1 RNA拷贝/毫升）检测到的RNA阳性血浆样本比例和平均HIV-1 RNA水平显著高于NucliSens检测法（n = 56 [80%]；4.3 log10 HIV-1 RNA拷贝/毫升）或标准HIV监测检测法（n = 44 [63%]；平均RNA水平为3.8 log10 HIV-1 RNA拷贝/毫升）（所有P值均<0.05）。改良后的HIV监测检测法测得的HIV-1 RNA水平与NucliSens检测法（r = 0.76；P < 0.001）及标准HIV监测检测法（r = 0.57；P < 0.001）测得的水平显著相关，NucliSens检测法与标准HIV监测检测法测得的RNA水平也显著相关（r = 0.
